medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2024, Number 1

<< Back Next >>

Rev Nefrol Dial Traspl 2024; 44 (1)

The femoral artery: An alternative safe and effective cannulation localization in the angiographic treatment of dysfunctional arteriovenous fistulas. Single-center experience; long term outcomes

Rifat UF, Akın OO

Language: English
References: 24
Page: 3-9
PDF size: 194.98 Kb.


ABSTRACT

Background: There is no consensus on optimal puncture localization in percutaneous transluminal angioplasty (PTA), the primary treatment modality for treating dysfunctional arteriovenous fistulas (AVF). In this retrospective single-center study, we present the early and late results of our PTA interventions performed with femoral artery puncture to treat dysfunctional AVF. Material and Methods: This study included 29 hemodialysis patients diagnosed with AVF dysfunction between January 2016 and June 2021 and therefore underwent PTA with femoral artery puncture. The patient’s demographic, clinical, and outcome data were obtained from the hospital database and electronic records of the patient’s hemodialysis center. Results: 29 hemodialysis patients (72.4% male) who underwent PTA for AVF dysfunction were followed for 53.0 (47.0-58.0) months. The patients median age was 61 (IQR 55.0- 68.0). Paclitaxel-eluting balloon angioplasty was performed in 27 patients. The clinical success rate of the procedure was 93.1%. Local hematoma developed at the femoral artery puncture site in two patients. No other complications were observed. AVFs were still functional in 25 (82.8%) patients at the end of follow-up. The multivariate Cox regression analyses determined that anticoagulant/ antiaggregant drug noncompliance independently predicted recurrence. Conclusion: The PTA performed via the femoral artery puncture is an effective and safe treatment modality for AVF dysfunctions. The risk of recurrence is exceptionally high in non-compliant patients with antiaggregant/ anticoagulant treatment.


REFERENCES

  1. Jager KJ, Kovesdy C, Langham R, Rosenberg M,Jha V, Zoccali C. A single number for advocacy andcommunication worldwide, more than 850 millionindividuals have kidney diseases. Oxford UniversityPress; 2019:1803-5.

  2. Lok CE, Huber TS, Lee T, Shenoy S, Yevzlin AS,Abreo K, et al. KDOQI clinical practice guidelinefor vascular access: 2019 update. Am J Kidney Dis.2020;75(4):S1-S164.

  3. Lookstein RA, Haruguchi H, Ouriel K, WeinbergI, Lei L, Cihlar S, et al. Drug-coated balloons fordysfunctional dialysis arteriovenous fistulas. N Engl JMed. 2020;383(8):733-42.

  4. Malka KT, Flahive J, Csizinscky A, Aiello F, SimonsJP, Schanzer A, et al. Results of repeated percutaneousinterventions on failing arteriovenous fistulas andgrafts and factors affecting outcomes. J Vasc Surg.2016;63(3):772-7.

  5. Asif A, Gadalean FN, Merrill D, Cherla G, CipleuCD, Epstein DL, et al. Inflow stenosis in arteriovenousfistulas and grafts: a multicenter, prospective study.Kidney Int. 2005;67(5):1986-92.

  6. Caplice NM, Wang S, Tracz M, Croatt AJ, GrandeJP, Katusic ZS, et al. Neoangiogenesis and thepresence of progenitor cells in the venous limb of anarteriovenous fistula in the rat. Am J Physiol RenalPhysiol. 2007;293(2):F470-F5.

  7. Mezzano D, Pais EO, Aranda E, Panes O,Downey P, Ortiz M, et al. Inflammation, nothyperhomocysteinemia, is related to oxidative stressand hemostatic and endothelial dysfunction in uremia.Kidney Int. 2001;60(5):1844-50.

  8. Croatt AJ, Grande JP, Hernandez MC, Ackerman AW,Katusic ZS, Nath KA. Characterization of a model of anarteriovenous fistula in the rat: the effect of L-NAME.Am J Pathol. 2010;176(5):2530-41.

  9. Asif A, Lenz O, Merrill D, Cherla G, Cipleu C, EllisR, et al. Percutaneous management of perianastomoticstenosis in arteriovenous fistulae: results of a prospectivestudy. Kidney Int. 2006;69(10):1904-9.

  10. Hammes M. Hemodynamic and biologic determinatesof arteriovenous fistula outcomes in renal failurepatients. Biomed Res Int. 2015;2015.

  11. Çildağ MB, Köseoğlu ÖFK, Akdam H, YeniçerioğluY. The primary patency of drug-eluting balloon versusconventional balloon angioplasty in hemodialysispatients with arteriovenous fistula stenosis. Jpn J Radiol.2016;34(10):700-4.

  12. Diskin CJ. Novel insights into the pathobiology ofvascular access–do they translate into improved care?Blood Purif. 2010;29(2):216-29.

  13. Lee T, Roy-Chaudhury P. Advances and newfrontiers in the pathophysiology of venous neointimalhyperplasia and dialysis access stenosis. Adv ChronicKidney Dis. 2009;16(5):329-38.

  14. Bittl JA. Catheter interventions for hemodialysis fistulasand grafts. JACC Cardiovasc Interv. 2010;3(1):1-11.

  15. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM.The elephant in uremia: oxidant stress as a unifyingconcept of cardiovascular disease in uremia. Kidney Int.2002;62(5):1524-38.

  16. Ghiadoni L, Cupisti A, Huang Y, Mattei P, CardinalH, Favilla S, et al. Endothelial dysfunction andoxidative stress in chronic renal failure. J Nephrol.2004;17(4):512-9.

  17. Bolton CH, Downs LG, Victory JG, DwightJF, Tomson CR, Mackness MI, et al. Endothelialdysfunction in chronic renal failure: roles of lipoproteinoxidation and pro‐inflammatory cytokines. NephrolDial Transplant. 2001;16(6):1189-97.

  18. Kohler TR, Toleikis PM, Gravett DM, AvelarRL. Inhibition of neointimal hyperplasia in a sheepmodel of dialysis access failure with the bioabsorbableVascular Wrap paclitaxel-eluting mesh. J Vasc Surg.2007;45(5):1029-38. e3.

  19. Katsanos K, Karnabatidis D, Kitrou P, SpiliopoulosS, Christmas N, Siablis D. Paclitaxel-coated balloonangioplasty vs. plain balloon dilation for the treatmentof failing dialysis access: 6-month interim results froma prospective randomized controlled trial. J EndovascTher. 2012;19(2):263-72.

  20. Duijm LE, Liem YS, van der Rijt RH, Nobrega FJ,van den Bosch HC, Douwes-Draaijer P, et al. Inflowstenosis in dysfunctional hemodialysis access fistulaeand grafts. Am J Kidney Dis. 2006;48(1):98-105.

  21. Gupta T, Paul N, Kolte D, Harikrishnan P,Khera S, Aronow WS, et al. Association of chronicrenal insufficiency with in‐hospital outcomes afterpercutaneous coronary intervention. J Am Heart Assoc.2015;4(6):e002069.

  22. Tonelli M, Karumanchi SA, Thadhani R. Epidemiologyand mechanisms of uremia-related cardiovasculardisease. Circulation. 2016;133(5):518-36.

  23. Aziz EF, Pulimi S, Coleman C, Florita C, Musat D,Tormey D, et al. Increased vascular access complicationsin patients with renal dysfunction undergoingpercutaneous coronary procedures using arteriotomyclosure devices. J Invasive Cardiol. 2010;22(1):8-13.

  24. He J, Reilly M, Yang W, Chen J, Go AS, Lash JPet al. Risk factors for coronary artery calcium amongpatients with chronic kidney disease (from the ChronicRenal Insufficiency Cohort Study). Am J Cardiol.2012;110(12):1735-41.




2020     |     www.medigraphic.com